Horst Sievert
COI disclosure
Disclosure: I am Horst Sievert, the subject of this draft. To avoid conflict of interest issues, I have prepared this draft with careful attention to neutrality and reliable sourcing.
The article text is based on independent, verifiable sources (peer-reviewed journals, professional society websites, and independent faculty profiles). Promotional language has been avoided, and all claims are supported by citations.
I kindly ask experienced reviewers to evaluate this draft for compliance with Wikipedia’s notability and BLP (Biographies of Living Persons) standards. Thank you for your time and support.
This template is misplaced. It belongs on the talk page: Talk:Horst Sievert.
| This article must adhere to the biographies of living persons (BLP) policy, even if it is not a biography, because it contains material about living persons. Contentious material about living persons that is unsourced or poorly sourced must be removed immediately from the article and its talk page, especially if potentially libellous. If such material is repeatedly inserted, or if you have other concerns, please report the issue to this noticeboard.If you are a subject of this article, or acting on behalf of one, and you need help, please see this help page. |
| Horst Sievert | |
|---|---|
| File:Horst Sievert.pngHorst Sievert.png Horst Sievert (2025) | |
| Born | 1954 |
| 🏳️ Nationality | German |
| 💼 Occupation | |
| Known for | Structural heart interventions; transcatheter valve therapies; PFO/LAA closure; peripheral vascular interventions; renal denervation |
Horst Sievert (born 1954) is a German interventional cardiologist based in Frankfurt am Main. He is the founder and director of the CardioVascular Center Frankfurt (CVC). Sievert is recognized internationally for his contributions to structural heart disease interventions, coronary and peripheral vascular procedures, transcatheter valve therapies, and minimally invasive catheter-based cardiovascular treatments.[1][2]
Career
Sievert began his career as chief of the Department of Interventional Cardiology and Angiology at the Herz- und Kreislaufzentrum Rotenburg an der Fulda in 1990, one of Germany’s largest centers for interventional cardiology.[3] In 1993, he joined the Cardioangiologisches Centrum Bethanien (CCB) in Frankfurt.[4] He founded the CardioVascular Center Frankfurt (CVC) in 2003 and remains its director.[5] From 2006 to 2009, Sievert held a part-time clinical appointment at Washington Hospital Center in Washington, DC.[6] Between 2012 and 2014, he was involved in the early clinical implementation of transcatheter aortic valve replacement (TAVR) in mainland China.[7]
Research and clinical contributions
Sievert's expertise encompasses:
- Coronary interventions (PCI).
- Structural heart disease: closure of patent foramen ovale (PFO), atrial septal defect (ASD), left atrial appendage (LAA), and transcatheter valve therapies including TAVR, TMVR, TTVR.
- Peripheral vascular interventions including percutaneous transluminal angioplasty (PTA) and carotid stenting.
- Acute stroke therapies, with participation in multicenter trials on carotid stenting and embolic protection devices.[8]
- Device-based therapies like renal denervation, notably in the SYMPLICITY HTN-2 trial.[9]
He was one of the international investigators in the first Chinese TAVR clinical trial program.[10]
Sievert has been principal investigator in several multicentre clinical trials, including PROTECT AF, EWOLUTION, Amulet IDE, CHAMPION AF, LAAOS-4, CoreValve ADVANCE, BioVentrix Revivent, and CORCINCH.[11]
He has also advanced device-free and bioresorbable occlusion approaches, including the radiofrequency-mediated PFO closure (PARADIGM study) and evaluation of fully biodegradable occluders.[12][13]
He has contributed to key international consensus statements on left atrial appendage occlusion, patent foramen ovale closure, and peripheral artery disease.[14]
Conferences and education
Sievert founded and directs the annual CSI conference series held in Frankfurt, and co-directs the ICCA Stroke course. He co-founded the WIST Foundation, promoting international collaboration in stroke therapy.[15] He extended CSI conferences to Asia-Pacific and Africa to support training in structural and valvular heart interventions.[16]
Professional leadership
Sievert has served on the Executive Board of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) as Treasurer. He is faculty at multiple major international conferences, including TCT, EuroPCR, AHA Scientific Sessions, ACC, SCAI Scientific Sessions, and the DGK Congress.[17]
Awards and recognition
- TCT Geoffrey O. Hartzler Master Clinical Operator Award (2011).[18][19]
- PICS Achievement Award (2011).[20]
- Highly Cited Researcher (Clarivate/Web of Science, 2020).[21]
Selected publications
- Sievert H, Lesh MD, Trepels T, et al. Percutaneous left atrial appendage transcatheter occlusion in atrial fibrillation: early experience. J Am Coll Cardiol. 2002;39:2094–2099.
- Sievert H, et al. Transcatheter closure of patent foramen ovale after cryptogenic stroke. Circulation. 2001;103:947–953.
- Holmes DR, Reddy VY, Sievert H, et al. Percutaneous closure of the left atrial appendage versus warfarin for atrial fibrillation. Lancet. 2009;374:534–542.
- Reddy VY, Sievert H, Halperin J, et al. Percutaneous LAA closure vs warfarin for AF: randomized clinical trial. JAMA. 2014;312:1988–1998.
- Esler M, Krum H, Sievert H, et al. Renal sympathetic denervation in resistant hypertension (SYMPLICITY HTN-2). Lancet. 2010;376:1903–1909.
References
- ↑ "Prof. Dr. Horst Sievert – CVC Frankfurt Team". CVC Frankfurt. Retrieved 2025-02-21.
- ↑ "Horst Sievert Profile". Radcliffe Cardiology. Retrieved 2025-09-27.
- ↑ "Prof. Dr. Horst Sievert – CVC Frankfurt Team". CVC Frankfurt. Retrieved 2025-02-21.
- ↑ Sievert, H (2012). "Transcatheter closure of patent foramen ovale using the Figulla device". EuroIntervention. 8: 609–615. doi:10.4244/EIJV8I5A96.
- ↑ "Prof. Dr. Horst Sievert – PCRonline Faculty". EuroPCR. Retrieved 2025-02-21.
- ↑ Sievert, H (2007). "Percutaneous closure of the left atrial appendage in patients with atrial fibrillation". Circulation. 116: 447–454. doi:10.1161/CIRCULATIONAHA.106.686915.
- ↑ "Venus Medtech History". Venus Medtech. Retrieved 2025-02-21.
- ↑ Clinical Trials at CVC Frankfurt – Status February 2025 (Report). CVC Frankfurt. 2025-02-17.
- ↑ Esler, M; Krum, H; Sievert, H (2010). "Renal sympathetic denervation in patients with hypertension (SYMPLICITY HTN-2 trial)". Lancet. 376: 1903–1909. doi:10.1016/S0140-6736(10)62039-9.
- ↑ Zhou, D; Sievert, H (2015). "Transcatheter aortic valve implantation in China: first multicentre trial". Catheterization and Cardiovascular Interventions. 85: 920–927. doi:10.1002/ccd.25874.
- ↑ Clinical Trials at CVC Frankfurt – Status February 2025 (Report). CVC Frankfurt. 2025-02-17.
- ↑ Sievert, H (2007). "Transcatheter closure of patent foramen ovale without an implant: initial clinical experience (PARADIGM study)". Circulation. 116: 1701–1706. doi:10.1161/CIRCULATIONAHA.107.709444.
- ↑ "World's First Absorbable PFO Occluder in Action – Live from CSI Frankfurt". Lepu Medical. Retrieved 2025-09-22.
- ↑ Glikson, M (2020). "EHRA/EAPCI consensus statement on catheter-based left atrial appendage occlusion". EuroIntervention. 15: 1133–1180. doi:10.4244/EIJY19M08_01.
- ↑ "WIST Foundation – About". WIST Foundation. Retrieved 2025-09-22.
- ↑ "CSI Africa". CSI Congress. Retrieved 2025-09-22.
- ↑ "EAPCI Executive Board 2010–2012". EuroIntervention. 7: 103–105. 2011. doi:10.4244/EIJV7I1A18.
- ↑ "Master Operator Award". TCT Conference. Retrieved 2025-09-25.
- ↑ "Horst Sievert, MD, PhD, presented with Master Clinical Operator Award". ScienceX. 2011-11-08. Retrieved 2025-09-27.
- ↑ "PICS Achievement Award – 2011: Horst Sievert". PICS Society. Retrieved 2025-09-22.
- ↑ "Highly Cited Researchers 2020". Web of Science. Retrieved 2025-09-27.
Category:Living people Category:1954 births Category:German cardiologists Category:Interventional cardiology
This article "Horst Sievert" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Horst Sievert. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
